YS Biopharma (YS) Set to Announce Quarterly Earnings on Friday

YS Biopharma (NASDAQ:YS) is scheduled to issue its quarterly earnings data before the market opens on Friday, April 19th.

YS Biopharma (NASDAQ:YS) last posted its earnings results on Monday, January 22nd. The company reported ($0.16) earnings per share (EPS) for the quarter. The firm had revenue of $13.64 million for the quarter. On average, analysts expect YS Biopharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

YS Biopharma Stock Performance

Shares of NASDAQ YS traded up $0.08 during trading on Wednesday, hitting $0.94. The stock had a trading volume of 413,726 shares, compared to its average volume of 199,102. YS Biopharma has a 12 month low of $0.35 and a 12 month high of $2.37. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.09 and a current ratio of 1.41. The firm has a fifty day moving average of $0.61 and a two-hundred day moving average of $0.57.

Institutional Investors Weigh In On YS Biopharma

Several institutional investors have recently added to or reduced their stakes in YS. FMR LLC purchased a new stake in YS Biopharma during the first quarter valued at about $1,864,000. Barclays PLC purchased a new stake in shares of YS Biopharma in the second quarter worth about $150,000. Finally, XTX Topco Ltd purchased a new stake in shares of YS Biopharma in the second quarter worth about $31,000. 52.64% of the stock is owned by hedge funds and other institutional investors.

YS Biopharma Company Profile

YS Biopharma Co, Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001.